Özel Yaş Gruplarında Meme Kanseri Yönetimi
Özet
Meme kanseri yönetimi, hastanın kronolojik yaşına bağlı olarak belirgin biyolojik ve klinik farklılıklar sergilemekte olup genç (<40 yaş) ve ileri yaş (>75 yaş) popülasyonlarında tamamen farklı stratejik yaklaşımlar gerektirir. Genç hastalarda rutin tarama programlarının bulunmaması ve yoğun meme dokusu yapısı, tanıların sıklıkla interval dönemde ve ileri evrelerde konulmasına yol açmaktadır. Bu gruptaki tümörler biyolojik olarak daha hırçın, yüksek gradlı, yüksek proliferatif indekse sahip ve hormon reseptörü negatif olma eğilimindedir. Gençlerde genetik yatkınlığın ve BRCA mutasyonlarının tespiti; cerrahi zamanlamayı, neoadjuvan kemoterapi planlarını ve radyoterapi kararlarını doğrudan yönlendirirken, fertilite korunması ve kozmetik beklentiler yönetim sürecinde hayati birer unsur olarak öne çıkar. Diğer taraftan, uzayan insan ömrüyle sıklığı artan ileri yaş grubunda da tarama programlarının erken sonlandırılması ve bilişsel bozukluklar nedeniyle genellikle geç evrede tanı konulur. Yaşlı hastaların tümörleri çoğunlukla hormon reseptörü pozitif ve daha az agresif seyirli olduğundan, adjuvan tedavinin merkezinde endokrin terapiler yer alır. Bu hastalarda kardiyak yetmezlik gibi ciddi komorbiditeler cerrahi toleransını ve kemoterapi rejimlerini kısıtlamakta, kanser dışı nedenlerle ölüm riski yüksek olduğundan, yaşam kalitesini optimize etmek adına lokal tedavilerin küçültülmesi ve de-eskalasyon stratejileri tercih edilmektedir.
Breast cancer management exhibits profound biological and clinical variations based on chronological age, necessitating highly specialized strategic frameworks for both young (<40 years) and elderly (>75 years) patient cohorts. In young adults, exclusion from standard screening protocols combined with high breast tissue density frequently causes delayed diagnoses at advanced intervals. Tumors in these younger women are biologically aggressive, demonstrating higher histological grades, high proliferative indices, and frequent hormone receptor negativity. Furthermore, evaluating genetic predispositions like BRCA mutations is vital since they directly dictate surgical parameters, neoadjuvant chemotherapy timelines, and radiotherapeutic applications, while fertility preservation and cosmetic outcomes remain critically integrated social priorities. Conversely, although prolonged life expectancies increase incidence in the elderly, screening cessation and cognitive declines often result in late-stage presentations. Biologically, senescent tumors are mostly hormone receptor-positive and low-risk, making endocrine therapy the absolute cornerstone of clinical care. Because severe comorbidities like cardiac limitations restrict standard cytotoxic chemotherapy and general anesthesia, and non-cancer mortality risks outpace cancer deaths, management carefully prioritizes de-escalation of regional radiation and simplified surgical procedures to sustain long-term quality of life.
Referanslar
Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z: SEER cancer statistics review, 1975–2012. National Cancer Institute 2014.
Society AC: Breast cancer facts & figures 2019–2020. Am Cancer Soc 2019:1-44.
Greif JM: Mammographic screening for breast cancer: An invited review of the benefits and costs. The Breast 2010, 19(4):268-272.
Anderson WF, Jatoi I, Sherman ME: Qualitative age interactions in breast cancer studies: mind the gap. Journal of Clinical Oncology 2009, 27(32):5308.
Pollán M: Epidemiology of breast cancer in young women. Breast cancer research and treatment 2010, 123(1):3-6.
Kalager M, Zelen M, Langmark F, Adami H-O: Effect of screening mammography on breast-cancer mortality in Norway. New England Journal of Medicine 2010, 363(13):1203-1210.
Network NCC: NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2022. In.
McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers 2015, 7(2):908-929.
Osako T, Iwase T, Takahashi K, Iijima K, Miyagi Y, Nishimura S, Tada K, Makita M, Akiyama F, Sakamoto G: Diagnostic mammography and ultrasonography for palpable and nonpalpable breast cancer in women aged 30 to 39 years. Breast cancer 2007, 14(3):255-259.
Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA: Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. Journal of the American College of surgeons 2009, 208(3):341-347.
Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ: US breast cancer mortality trends in young women according to race. Cancer 2015, 121(9):1469-1476.
Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of clinical oncology 2008, 26(20):3324-3330.
Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, Altman DG, Durcan L, Simmonds P, Lawrence G: Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: the POSH study. Journal of the national cancer institute 2013, 105(13):978-988.
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A: PD-L1 expression in triple-negative breast cancer. Cancer immunology research 2014, 2(4):361-370.
Rosenberg SM, Partridge AH: Management of breast cancer in very young women. The Breast 2015, 24:S154-S158.
Cancer CGoHFiB: Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. The Lancet 2001, 358(9291):1389-1399.
Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. Journal of Clinical Oncology 2002, 20(6):1480-1490.
McGuire KP, Mamounas EP: Management of hereditary breast cancer: ASCO, ASTRO, and SSO guideline. Annals of Surgical Oncology 2020, 27(6):1721-1723.
Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, Gentilini O, Peccatori F, Fourquet A, Delaloge S: The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. European journal of cancer 2012, 48(18):3355-3377.
Doherty J, Bonadies DC, Matloff ET: Testing for hereditary breast cancer: panel or targeted testing? Experience from a clinical cancer genetics practice. Journal of genetic counseling 2015, 24(4):683-687.
Barry M, Kell M: Radiotherapy and breast reconstruction: a meta-analysis. Breast cancer research and treatment 2011, 127(1):15-22.
Ho AY, Hu ZI, Mehrara BJ, Wilkins EG: Radiotherapy in the setting of breast reconstruction: types, techniques, and timing. The Lancet Oncology 2017, 18(12):e742-e753.
Jagsi R, Momoh AO, Qi J, Hamill JB, Billig J, Kim HM, Pusic AL, Wilkins EG: Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction. JNCI: Journal of the National Cancer Institute 2018, 110(2):157-165.
Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RdNG, Cotti GC, Hoff PM, Fragoso MCBV, Estevez-Diz MdP: Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li–Fraumeni syndrome). Familial Cancer 2020, 19(1):47-53.
Lazzari G, Buono G, Zannino B, Silvano G: Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues? Breast Cancer: Targets and Therapy 2021, 13:299.
Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL: The role of BRCA mutation testing in determining breast cancer therapy. Nature reviews Clinical oncology 2010, 7(12):708-717.
McCann KE, Hurvitz SA: Advances in the use of PARP inhibitor therapy for breast cancer. Drugs in context 2018, 7.
Ozyigit G, Gultekin M: Current role of modern radiotherapy techniques in the management of breast cancer. World journal of clinical oncology 2014, 5(3):425.
Kurtz J: The curative role of radiotherapy in the treatment of operable breast cancer. European Journal of Cancer 2002, 38(15):1961-1974.
Winters ZE, Benson JR, Pusic AL: A systematic review of the clinical evidence to guide treatment recommendations in breast reconstruction based on patient-reported outcome measures and health-related quality of life. Annals of surgery 2010, 252(6):929-942.
Heneghan H, Prichard R, Lyons R, Regan P, Kelly J, Malone C, McLaughlin R, Sweeney K, Kerin M: Quality of life after immediate breast reconstruction and skin-sparing mastectomy–a comparison with patients undergoing breast conserving surgery. European Journal of Surgical Oncology (EJSO) 2011, 37(11):937-943.
Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert‐Toft M, Melbye M: Effect of breast‐conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004, 100(4):688-693.
Frandsen J, Ly D, Cannon G, Suneja G, Matsen C, Gaffney DK, Wright M, Kokeny KE, Poppe MM: In the modern treatment era, is breast conservation equivalent to mastectomy in women younger than 40 years of age? A multi-institution study. International Journal of Radiation Oncology* Biology* Physics 2015, 93(5):1096-1103.
Heemskerk-Gerritsen BA, Jager A, Koppert LB, Obdeijn A, Collée M, Meijers-Heijboer HE, Jenner DJ, Oldenburg HS, van Engelen K, de Vries J: Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment 2019, 177(3):723-733.
Heemskerk‐Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, Kets CM, Keymeulen KB, Koppert LB, Meijers‐Heijboer HE: Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. International journal of cancer 2015, 136(3):668-677.
Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, Buchan I, Howell A, Evans DGR: Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast cancer research and treatment 2013, 142(3):611-618.
Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV: American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Annals of surgical oncology 2012, 19(10):3144-3151.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. The lancet oncology 2014, 15(12):1303-1310.
van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, Poortmans P, Strobbe LJ, Siesling S: 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. The Lancet Oncology 2016, 17(8):1158-1170.
Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, White J, Harris JR: Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Practical radiation oncology 2017, 7(2):73-79.
Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K, Horst K, Moran J: Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Practical radiation oncology 2018, 8(3):145-152.
Group EBCTC: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 2005, 365(9472):1687-1717.
De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. edn.: Centre for Reviews and Dissemination (UK); 2008.
Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD: Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2–positive breast cancer: Results from a herceptin adjuvant trial. Journal of clinical oncology 2013, 31(21):2692-2698.
Ademuyiwa FO, Cyr A, Ivanovich J, Thomas MA: Managing breast cancer in younger women: challenges and solutions. Breast Cancer: Targets and Therapy 2016, 8:1.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet 2013, 381(9869):805-816.
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ: Adjuvant ovarian suppression in premenopausal breast cancer. New England Journal of Medicine 2015, 372(5):436-446.
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer Jr CE, Dees EC, Goetz MP: Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. New England Journal of Medicine 2019, 380(25):2395-2405.
Piccart M, van't Veer LJ, Poncet C, Cardozo JML, Delaloge S, Pierga J-Y, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA: 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. The Lancet Oncology 2021, 22(4):476-488.
Hery C, Ferlay J, Boniol M, Autier P: Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Annals of Oncology 2008, 19(6):1187-1194.
Ries LAG, Young Jr JL, Keel GE, Eisner MP, Lin YD, Horner M-JD: Cancer survival among adults: US SEER program, 1988–2001. Patient and tumor characteristics SEER Survival Monograph Publication 2007, 7:6215.
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E: Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. The lancet oncology 2014, 15(1):23-34.
Markopoulos C, van de Water W: Older patients with breast cancer: is there bias in the treatment they receive? Therapeutic Advances in Medical Oncology 2012, 4(6):321-327.
Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Annals of internal medicine 1994, 120(2):104-110.
de Glas NA, de Craen AJ, Bastiaannet E, Op’t Land EG, Kiderlen M, van de Water W, Siesling S, Portielje JE, Schuttevaer HM, de Bock GTH: Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study. Bmj 2014, 349.
Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. JNCI: Journal of the National Cancer Institute 2000, 92(7):550-556.
Lawrence G, Kearins O, Lagord C, Cheung S, Sidhu J, Sagar C: The second all breast cancer report. Focussing on inequalities: variation in breast cancer outcomes with age and deprivation National Cancer Intelligence Network, London 2011.
Aapro M, Wildiers H: Triple-negative breast cancer in the older population. Annals of oncology 2012, 23:vi52-vi55.
Wyld L, Garg D, Kumar I, Brown H, Reed M: Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. British journal of cancer 2004, 90(8):1486-1491.
Morgan J, Richards P, Ward S, Francis M, Lawrence G, Collins K, Reed M, Wyld L: Case-mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer. Journal of British Surgery 2015, 102(9):1056-1063.
Reed M, Audisio R, Wyld L: The role of surgery in the treatment of older women with breast cancer. Clinical Oncology 2009, 21(2):103-110.
Kaur P, Santillan AA, McGuire K, Turaga KK, Shamehdi C, Meade T, Ramos D, Mathias M, Parbhoo J, Davis M: The surgical treatment of breast cancer in the elderly: a single institution comparative review of 5235 patients with 1028 patients≥ 70 years. The Breast Journal 2012, 18(5):428-435.
Caretta-Weyer H, Greenberg CG, Wilke LG, Weiss J, LoConte NK, Decker M, Steffens NM, Smith MA, Neuman HB: Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis. Annals of surgical oncology 2013, 20(13):4145-4152.
Rutgers EJ, Donker M, Straver ME, Meijnen P, Van De Velde CJ, Mansel RE, Westenberg H, Orzalesi L, Bouma WH, Van der Mijle H: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023). In.: American Society of Clinical Oncology; 2013.
Cortina CS: De-Escalation of Local-Regional Therapy for Older Breast Cancer Patients. Current Breast Cancer Reports 2020, 12(4):344-350.
Sun J, Loftus LS, Lee MC: ASO Author Reflections: The De-Escalation of Sentinel Node Biopsy for Breast Cancer. Annals of Surgical Oncology 2020, 27(3):838-839.
Christian N, Heelan Gladden A, Friedman C, Gleisner‐Patton A, Murphy C, Kounalakis N, Ahrendt G: Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormone‐positive breast cancer. The Breast Journal 2020, 26(2):133-138.
Thompson J, Le J, Hop A, Melnik M, Paulson J, Wright GP: Impact of Choosing Wisely recommendations on sentinel lymph node biopsy and postoperative radiation rates in women over age 70 years with hormone-positive breast cancer. Annals of Surgical Oncology 2021, 28(10):5716-5722.
Laporta R, Sorotos M, Longo B, di Pompeo FS: Breast reconstruction in elderly patients: risk factors, clinical outcomes, and aesthetic results. Journal of Reconstructive Microsurgery 2017, 33(04):257-267.
Maruccia M, Di Taranto G, Onesti MG: One‐stage muscle‐sparing breast reconstruction in elderly patients: a new tool for retaining excellent quality of life. The Breast Journal 2018, 24(2):180-183.
Group EBCTC: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The lancet 2011, 378(9793):771-784.
Powell DE, Cochrane RA, Davie MW: Does anastrozole affect bone resorption similarly in early and late postmenopausal women? Calcified tissue international 2011, 88(3):223-230.
Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R: Prevention of aromatase inhibitor–induced bone loss using risedronate: the SABRE trial. Journal of clinical oncology 2010, 28(6):967-975.
Markopoulos C, Tzoracoleftherakis E, Koukouras D, Venizelos B, Zobolas V, Misitzis J, Xepapadakis G, Gogas H: Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. Journal of cancer research and clinical oncology 2012, 138(9):1569-1577.
Aapro M, Tjulandin S, Bhar P, Gradishar W: Weekly nab-paclitaxel is safe and effective in≥ 65 years old patients with metastatic breast cancer: a post-hoc analysis. The Breast 2011, 20(5):468-474.
von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J: A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer 2015, 121(20):3639-3648.
Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM: Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. The Lancet Oncology 2015, 16(3):266-273.
Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. New England Journal of Medicine 2004, 351(10):971-977.
